Safety and benefit considerations for menopausal hormone therapy

Area of Science:

• Reproductive Endocrinology
• Pharmacology
• Women's Health

Background:

• Hormone therapy (HT) benefits and risks are established through randomized trials.
• Clinical practice and research reveal HT safety is influenced by patient age, timing of initiation, and specific treatment regimens.
• The safety profile of HT is complex, with varying effects based on different formulations and routes of administration.

Purpose of the Study:

• To review the safety of hormone therapy (HT) concerning cardiovascular disease, thrombosis, endometrial health, breast health, and cognition.
• To report on the differential safety effects of various estrogens (e.g., estradiol vs. conjugated equine estrogens) and progestogens (e.g., progesterone vs. synthetic progestins).

Main Methods:

• Review of data from observational studies, the Women's Health Initiative (WHI) trials and analyses, and subsequent randomized controlled trials.
• Analysis of studies comparing different estrogen and progestogen components of various HT regimens.
• Evaluation of safety data considering different administration routes and patient factors.

Main Results:

• Unexpected safety concerns with HT emerged from initial WHI findings.
• Subsequent WHI analyses and component studies revealed significant differences in safety profiles between estrogen-alone and estrogen-progestogen therapies.
• Differential safety effects were observed between estradiol and conjugated equine estrogens, as well as between natural progesterone and synthetic progestins.

Conclusions:

• The perceived safety of HT has evolved significantly with accumulating evidence.
• Individualized HT decisions require balancing risks and benefits, considering specific patient factors.
• Optimal HT selection involves careful consideration of the chosen estrogen, progestogen, dosage, and route of administration based on current safety data.